NCT04373616: A trial that was reported late by AC Immune SA
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04373616 |
|---|---|
| Title | A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 31, 2020 |
| Completion date | April 30, 2024 |
| Required reporting date | April 30, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 25, 2021 |
| Days late | None |